- Conditions
- Asthma
- Interventions
- GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg, Placebo MDI, Spiriva Respimat 2.5 μg
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 1,077 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 232
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 188 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2377–2400
of 12,562
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease
- Interventions
- semagacestat
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 38 more
- Conditions
- Neoplasms, Cancer
- Interventions
- Not listed
- Lead sponsor
- GRAIL, Inc.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 15,254 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2024
- U.S. locations
- 139
- States / cities
- Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 105 more
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
- Drug · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Fibromyalgia
- Interventions
- Desvenlafaxine Sustained Release
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2007
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Interventions
- Placebo, Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 18
- States / cities
- Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Florbetapir F 18 PET Scan
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 77
- States / cities
- Anaheim, California • Imperial, California • Irvine, California + 59 more
- Conditions
- Breast Cancer
- Interventions
- TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
- Drug
- Lead sponsor
- Agendia
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more
- Conditions
- Low Back Pain
- Interventions
- Tanezumab 20 mg, Tanezumab 10 mg
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 149
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 99 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 21
- States / cities
- Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more
- Conditions
- Actinic Keratosis
- Interventions
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Drug · Other
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Encino, California • Los Angeles, California + 20 more
- Conditions
- Acne Vulgaris
- Interventions
- FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
- Combination Product · Drug · Other
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 35
- States / cities
- Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
- Conditions
- Pelvic Floor Disorders
- Interventions
- Botulinum neurotoxin, High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
- Drug · Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
- Conditions
- Cervical Cancer
- Interventions
- CHW and Self-sampling for Cervical Cancer, Mailed Self Sampler
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Mixed Epithelial Tumor, Malignant Ovarian Mucinous Tumor, Malignant Ovarian Neoplasm, Malignant Ovarian Serous Tumor, Malignant Ovarian Transitional Cell Tumor, Ovarian Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 131
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 99 more
- Conditions
- Low Back Pain
- Interventions
- Tanezumab 20 mg IV, Placebo for naproxen, Tanezumab 10 mg IV, Tanezumab 5 mg IV, Placebo for tanezumab, Naproxen
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 135
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104,308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Depressive Disorder, Major
- Interventions
- Vortioxetine, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 61
- States / cities
- Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
- Conditions
- Plaque Psoriasis
- Interventions
- Envudeucitinib, Placebo, Apremilast
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
- Conditions
- Posterolateral Thoracotomy, Postoperative Pain
- Interventions
- EXPAREL 266 mg, Placebo
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Miami, Florida • Shreveport, Louisiana • Fargo, North Dakota + 4 more
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 72
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more
- Conditions
- Transplant; Failure, Kidney
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Pediatric Growth Hormone Deficiency
- Interventions
- MOD-4023, Somatropin
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 18
- States / cities
- Orange, California • Aurora, Colorado • Centennial, Colorado + 15 more